Y-mAbs Therapeutics IncNASDAQ:YMAB
- LAST PRICE4.4400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.3000/ 5
- Ask / Lots4.7100/ 3
- Open / Previous Close4.5000 / 4.4400
- Day Range
- 52 Week Range
- Volume486,249
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | YMAB |
|---|---|---|
| 09:32 ET | 9857 | 4.5599 |
| 09:35 ET | 1043 | 4.525 |
| 09:37 ET | 509 | 4.6 |
| 09:39 ET | 100 | 4.61 |
| 09:42 ET | 1177 | 4.53 |
| 09:44 ET | 294 | 4.55 |
| 09:46 ET | 1100 | 4.55 |
| 09:48 ET | 1087 | 4.55 |
| 09:50 ET | 2848 | 4.54 |
| 09:51 ET | 200 | 4.5346 |
| 09:55 ET | 600 | 4.51 |
| 09:57 ET | 100 | 4.53 |
| 10:04 ET | 300 | 4.4934 |
| 10:06 ET | 400 | 4.51 |
| 10:08 ET | 8551 | 4.53 |
| 10:11 ET | 1702 | 4.525 |
| 10:13 ET | 100 | 4.52 |
| 10:18 ET | 500 | 4.5001 |
| 10:20 ET | 4308 | 4.45 |
| 10:22 ET | 8556 | 4.47 |
| 10:26 ET | 7836 | 4.43 |
| 10:27 ET | 603 | 4.42 |
| 10:29 ET | 1929 | 4.4 |
| 10:31 ET | 4309 | 4.4 |
| 10:33 ET | 600 | 4.4 |
| 10:36 ET | 100 | 4.4 |
| 10:38 ET | 400 | 4.4 |
| 10:40 ET | 1300 | 4.395 |
| 10:42 ET | 300 | 4.395 |
| 10:44 ET | 819 | 4.39 |
| 10:45 ET | 4000 | 4.4 |
| 10:47 ET | 4349 | 4.39 |
| 10:49 ET | 200 | 4.39 |
| 10:54 ET | 3310 | 4.4 |
| 10:56 ET | 3756 | 4.39 |
| 10:58 ET | 1100 | 4.4 |
| 11:00 ET | 600 | 4.4 |
| 11:02 ET | 1675 | 4.4 |
| 11:03 ET | 1796 | 4.4 |
| 11:05 ET | 6541 | 4.39 |
| 11:07 ET | 4200 | 4.42 |
| 11:09 ET | 1954 | 4.4 |
| 11:12 ET | 10398 | 4.4 |
| 11:16 ET | 2724 | 4.39 |
| 11:18 ET | 712 | 4.4 |
| 11:20 ET | 3000 | 4.405 |
| 11:21 ET | 7648 | 4.41 |
| 11:23 ET | 1700 | 4.405 |
| 11:27 ET | 400 | 4.4 |
| 11:30 ET | 2874 | 4.4 |
| 11:32 ET | 200 | 4.4 |
| 11:34 ET | 4325 | 4.4 |
| 11:36 ET | 704 | 4.4 |
| 11:52 ET | 100 | 4.395 |
| 11:56 ET | 4696 | 4.4 |
| 11:57 ET | 2500 | 4.4 |
| 11:59 ET | 11383 | 4.41 |
| 12:03 ET | 100 | 4.41 |
| 12:06 ET | 1021 | 4.44 |
| 12:08 ET | 20100 | 4.4 |
| 12:12 ET | 4607 | 4.39 |
| 12:14 ET | 400 | 4.395 |
| 12:15 ET | 2099 | 4.4 |
| 12:17 ET | 600 | 4.385 |
| 12:19 ET | 1116 | 4.38 |
| 12:21 ET | 1200 | 4.38 |
| 12:26 ET | 200 | 4.385 |
| 12:28 ET | 1530 | 4.39 |
| 12:30 ET | 1312 | 4.4 |
| 12:32 ET | 30634 | 4.42 |
| 12:33 ET | 2308 | 4.46 |
| 12:35 ET | 100 | 4.465 |
| 12:37 ET | 1365 | 4.47 |
| 12:39 ET | 600 | 4.47 |
| 12:46 ET | 1372 | 4.47 |
| 12:48 ET | 400 | 4.48 |
| 12:53 ET | 71732 | 4.54 |
| 12:55 ET | 2442 | 4.5301 |
| 12:57 ET | 600 | 4.51 |
| 01:00 ET | 200 | 4.495 |
| 01:04 ET | 600 | 4.495 |
| 01:06 ET | 1468 | 4.475 |
| 01:11 ET | 3370 | 4.46 |
| 01:13 ET | 700 | 4.46 |
| 01:15 ET | 100 | 4.45 |
| 01:18 ET | 1085 | 4.47 |
| 01:27 ET | 1449 | 4.46 |
| 01:31 ET | 894 | 4.44 |
| 01:33 ET | 800 | 4.42 |
| 01:36 ET | 2147 | 4.4 |
| 01:38 ET | 300 | 4.42 |
| 01:40 ET | 526 | 4.43 |
| 01:44 ET | 300 | 4.42 |
| 01:45 ET | 300 | 4.42 |
| 01:47 ET | 1070 | 4.43 |
| 01:51 ET | 400 | 4.425 |
| 01:54 ET | 795 | 4.4234 |
| 01:58 ET | 300 | 4.425 |
| 02:00 ET | 100 | 4.43 |
| 02:03 ET | 1192 | 4.43 |
| 02:05 ET | 100 | 4.43 |
| 02:07 ET | 3150 | 4.43 |
| 02:09 ET | 200 | 4.43 |
| 02:12 ET | 1591 | 4.4 |
| 02:14 ET | 1300 | 4.4 |
| 02:16 ET | 300 | 4.41 |
| 02:18 ET | 100 | 4.41 |
| 02:23 ET | 2674 | 4.4 |
| 02:30 ET | 200 | 4.4 |
| 02:34 ET | 400 | 4.4 |
| 02:36 ET | 600 | 4.41 |
| 02:38 ET | 3759 | 4.41 |
| 02:39 ET | 100 | 4.43 |
| 02:41 ET | 400 | 4.42 |
| 02:43 ET | 200 | 4.415 |
| 02:45 ET | 1694 | 4.43 |
| 02:48 ET | 300 | 4.42 |
| 02:50 ET | 200 | 4.41 |
| 02:52 ET | 1641 | 4.42 |
| 02:57 ET | 1390 | 4.44 |
| 02:59 ET | 700 | 4.45 |
| 03:01 ET | 100 | 4.44 |
| 03:03 ET | 525 | 4.4573 |
| 03:10 ET | 324 | 4.46 |
| 03:12 ET | 424 | 4.47 |
| 03:14 ET | 624 | 4.46 |
| 03:15 ET | 200 | 4.46 |
| 03:17 ET | 100 | 4.46 |
| 03:19 ET | 400 | 4.46 |
| 03:21 ET | 1025 | 4.445 |
| 03:26 ET | 450 | 4.4474 |
| 03:28 ET | 400 | 4.45 |
| 03:30 ET | 841 | 4.45 |
| 03:32 ET | 400 | 4.44 |
| 03:33 ET | 200 | 4.455 |
| 03:35 ET | 900 | 4.46 |
| 03:37 ET | 500 | 4.47 |
| 03:39 ET | 324 | 4.47 |
| 03:42 ET | 5017 | 4.455 |
| 03:44 ET | 267 | 4.455 |
| 03:46 ET | 449 | 4.455 |
| 03:48 ET | 3938 | 4.44 |
| 03:51 ET | 4251 | 4.44 |
| 03:53 ET | 600 | 4.435 |
| 03:55 ET | 4604 | 4.43 |
| 03:57 ET | 4230 | 4.45 |
| 04:00 ET | 32210 | 4.44 |
Today
Yesterday
ALERT: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - YMAB, from 4 hours ago by Newsfile
4 hours ago by NewsfileYMAB ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm's Attorneys, Securities Fraud Class Action Filed, from 10 hours ago by GlobeNewswire
10 hours ago by GlobeNewswireY-MABS THERAPEUTICS, INC. (YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB), from 13 hours ago by Newsfile
13 hours ago by NewsfileBronstein, Gewirtz & Grossman, LLC Notifies Y-mAbs Therapeutics, Inc. (YMAB) Investors of Class Action and to Actively Participate, from 15 hours ago by Business Wire
15 hours ago by Business Wire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Y-mAbs Therapeutics Inc | 193.9M | -1.5x | --- |
KemPharm Inc | 190.1M | -5.3x | --- |
Ikena Oncology Inc | 162.4M | -3.0x | --- |
Affimed NV | 176.6M | -2.1x | --- |
Shattuck Labs Inc | 157.3M | -2.5x | --- |
XOMA Corp | 238.7M | 60.2x | --- |
Company Information
Y-mAbs Therapeutics, Inc. is a commercial-stage clinical biopharmaceutical company. It is focused on development and commercialization of antibody based therapeutic products for the treatment of cancer. The Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. The Company’s product pipeline includes DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and omburtamab, which targets tumors that express B7-H3. DANYELZA, which is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. It also develops Omburtamab, which is novel murine monoclonal antibody targeting B7-H3. The Company is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB, and in relapsed osteosarcoma.
Contact Information
- Headquarters
- 230 PARK AVENUE, SUITE 3350NEW YORK, NY, United States 10169
- Phone
- 212-847-9841
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- James Healy
- President, Interim Chief Executive Officer, Founder, Director, Head of Business Development and Strategy
- Thomas Gad
- Chief Financial Officer, Executive Vice President, Treasurer, Secretary
- Bo Kruse
- Chief Operating Officer, Senior Vice President
- Joris Wilms
- Senior Vice President, Chief Technical Officer
- Torben Lund-Hansen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $193.9M |
|---|---|
Revenue (TTM) | $43.4M |
Shares Outstanding | 43.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.69 |
EPS | $-3.06 |
Book Value | $4.12 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | 4.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -298.07% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
